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Abstract
The coxsackievirus and adenovirus receptor (CAR) is a crucial receptor for the entry of both
coxsackie B viruses and adenoviruses into host cells. CAR expression on tumor cells was reported
to be associated with their sensitivity to adenoviral infection, while it was considered as a surrogate
marker for monitoring and/or predicting the outcome of adenovirus-mediated gene therapy. The
aim of the present study was to evaluate the clinical significance of CAR expression in endometrial
adenocarcinoma. CAR expression was assessed immunohistochemically in tumoral samples of 41
endometrial adenocarcinoma patients and was statistically analyzed in relation to various
clinicopathological parameters, tumor proliferative capacity and patient survival. CAR positivity was
noted in 23 out of 41 (56%) endometrial adenocarcinoma cases, while high CAR expression in 8
out of 23 (35%) positive ones. CAR intensity of immunostaining was classified as mild in 11 (48%),
moderate in 10 (43%) and intense in 2 (9%) out of the 23 positive cases. CAR positivity was
significantly associated with tumor histological grade (p = 0.036), as well differentiated tumors
more frequently demonstrating no CAR expression. CAR staining intensity was significantly
associated with tumor histological type (p = 0.016), as tumors possessing squamous elements
presented more frequently intense CAR immunostaining. High CAR expression showed a trend to
be correlated with increased tumor proliferative capacity (p = 0.057). Patients with tumors
presenting moderate or intense CAR staining intensity were characterized by longer survival times
than those with mild one; however, this difference did not reach statistical significance. These data
reveal, for the first time, the expression of CAR in clinical material obtained from patients with
endometrial adenocarcinoma in relation to important clinicopathological parameters for their
management. As CAR appears to modulate the proliferation and characteristics of cancer cells, its
expression could be considered of possible clinical importance for future (gene) therapy
applications.
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The coxsackievirus and adenovirus receptor (CAR) is a 46-
kDa transmembrane protein, which functions as a pri-
mary receptor for both coxsackie B virus (CVB) and aden-
ovirus (Ad) [1]. This cell surface receptor plays a crucial
role in CVB and Ad entry into host cells [2]. CAR mediates
homotypic intercellular interactions, while in polarized
endothelial cells CAR is closely associated with the tight
junction, where it contributes to the barrier of paracellular
flow of solutes and macromolecules [3]. A strong correla-
tion of CAR levels with the viral sensitivity of several cell
types has been reported [4-6]. In fact, CAR has been
shown to be a docking site for Ad, thus acting as a key
receptor for the enhancement of the virus-to-host affinity
and the initiation of the virus internalization to the host
cell [7,8]. On cells lacking CAR, virus uptake takes place
with lower efficiency [7,9] due to the existence of a sec-
ondary pathway leading to the viral internalization [7,10].
The very promising use of Ad vectors in gene therapy,
since Ads are relatively safe, highly infectious, and capable
of delivering therapeutic genes to different cell types
[10,11], still faces a critical prerequisite, which is no other
than the identification of highly efficient and accurate sys-
tems for delivering the therapeutic genes into target cells
[12]. In this regard, CAR expression could be a surrogate
marker for monitoring and/or predicting the outcome of
gene therapy, while by increasing CAR levels, resistant
cells could become more sensitive to Ad infection [13].
However, only a limited number of studies concerning
CAR expression have been made on clinical tissue mate-
rial. In this aspect, Persson et al. presented an immunohis-
tochemical study in human normal brain and human
brain tumors, suggesting that neuroblastomas and medul-
loblastomas could be suitable for adenovirus-mediated
gene therapy [14,15]. Moreover, recent studies have sug-
gested a pathophysiological role for CAR in bladder can-
cer and glioma cells, rendering CAR as a membrane
receptor which conveys its signal into the nucleus and
results in cell proliferation suppression [16-18]. These
findings raise the question whether CAR expression could
be related to the tumor proliferative capacity or differenti-
ation amongst the different tumor cell types.
Endometrial adenocarcinoma is the most common malig-
nant tumor of the female tract and the fourth most com-
mon cancer in women following breast, colorectal and
lung cancer in the Western world [19]. A substantial
decrease in the incidence and mortality of endometrial
cancer seems unlikely in the next few years, as early detec-
tion and treatment modalities have not been proven to
possess a major impact on mortality [20]. Epigenetic
modification reagents, including DNA methyltransferase
and histone deacetylase inhibitors, when used alone or in
combination with conventional chemotherapy, seem to
be beneficial for endometrial cancer patients [21]. How-
ever, further research advancements are recommended to
bring about new strategies and technologies, which ulti-
mately improve the diagnosis and treatment of women
with endometrial cancer [21].
In the light of the above considerations, the present study
aimed to estimate the immunohistochemical CAR expres-
sion in tumoral specimens obtained from endometrial
adenocarcinoma patients. We also aimed to evaluate the
association of CAR expression and staining intensity with
various clinicopathological parameters, tumor prolifera-
tive capacity and patient survival.
Patients and Methods
Patients
Forty-one endometrial adenocarcinoma specimens
obtained from an equal number of patients who under-
went surgery due to endometrial cancer were included in
this study. None of the patients received any kind of anti-
cancer treatment prior to surgery. The mean age of the
patient cohort was 63.4 ± 9.6 years (median: 64 years,
range: 40–82 years). Tumors were typed according to the
presence or not of squamous elements. Three levels of dif-
ferentiation were used to classify grading as: well, moder-
ately and poorly differentiated. Tumors staging was
assessed according to the standards of the Federation
Internationationale de Gynecologistes et Obstetricianes
(FIGO) [22]. The patients were followed up, with the
length of the follow up varying from 22 to 94 months
(mean 65.51 ± 16.19 median 64 months). Twenty six
patients were followed up until death, while the remain-
ing 15 patients were remained disease free. All the exam-
ined clinicopathological parameters are reported in Tables
1, 2 and 3.
Immunohistochemistry
Immunostainings for CAR was performed on paraffin-
embedded tissue sections using a commercially available
rabbit anti-CAR monoclonal antibody (CAR H300, Santa
Cruz Biochemicals, Santa Cruz, CA, USA). Briefly, 4 μm
thick tissue sections were dewaxed in xylene and were
brought to water through graded alcohols. To remove the
endogenous peroxidase activity, sections were then
treated with freshly prepared 0.3% hydrogen peroxide in
methanol in the dark, for 30 minutes (min), at room tem-
perature. Non-specific antibody binding was then blocked
using Snipper, a specific blocking reagent for mouse pri-
mary antibodies (Sniper, Biocare Medical, Walnut, Creek,
CA, USA) for 5 min. The sections were then incubated for
1 hour (h), at room temperature, with the primary anti-
body, CAR, diluted 1:100, respectively, in phosphate buff-
ered saline (PBS). After washing three times with PBS,
sections were incubated at room temperature with bioti-
nylated linking reagent (Biocare Medical) for 10 min, fol-Page 2 of 8
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streptavidin label (Biocare Medical) for 10 min. The
resultant immune peroxidase activity was developed in
0.5% 3,3'-diaminobenzidine hydrochloride (DAB; Sigma,
Saint Louis, MO, USA) in PBS containing 0.03% hydrogen
peroxide for 3 min. Sections were counterstained with
Harris' hematoxylin and mounted in Entellan (Merck,
Darmstadt, Germany). An additional step of antigen
retrieval (citrate buffer at pH 6.1 and microwave heating)
was performed before incubation with the primary anti-
CAR antibody. Appropriate negative controls were per-
formed by omitting the primary antibody and/or substi-
Table 1: Associations between CAR positivity and clinicopathological characteristics of the 41 patients with endometrial 
adenocarcinoma
Clinicopathological characteristics CAR positivity
Negative (%) Positive (%) P-value
Patients 18 (44) 23 (56)
Age (mean ± SD), years 64.7 ± 7.5 62.4 ± 11.0 0.623
< 63 8 (20) 12 (29)
≥63 10 (24) 11 (27)
pStage (FIGO) 0.675
I 16 (40) 18 (44)
II 1 (2) 3 (8)
III 0 (0) 1 (2)
IV 1 (2) 1 (2)
Histological type 0.684
Positive for squamous elements 3 (8) 5 (12)
Negative for squamous elements 15 (36) 18 (44)
Histological grade 0.036
Well differentiated 7 (17) 3 (8)
Moderately differentiated 7 (17) 18 (44)
Poorly differentiated 4 (10) 2 (4)
Ki-67 protein statement 0.829
Ki-67 below mean (<40%) 10 (24) 12 (29)
Ki-67 over mean (≥ 40%) 8 (20) 11 (27)
Table 2: Associations between CAR overexpression and clinicopathological characteristics of the 23 CAR positive endometrial 
adenocarcinoma cases
Clinicopathological characteristics CAR expression
< 31% (%) ≥31% (%) P-value
Patients 15 (65) 8 (35)
Age (mean± SD), years 62.9 ± 12.1 61.5 ± 9.6 0.469
< 63 8 (35) 5 (22)
≥63 7 (30) 3 (13)
pStage (FIGO) 0.147
I 12 (52) 6 (27)
II 3 (13) 0 (0)
III 0 (0) 1 (4)
IV 0 (0) 1 (4)
Histological type 0.181
Positive for squamous elements 2 (9) 3 (13)
Negative for squamous elements 13 (56) 5 (22)
Histological grade 0.379
Well differentiated 3 (13) 0 (0)
Moderately differentiated 11 (48) 7 (31)
Poorly differentiated 1 (4) 1 (4)
Ki-67 protein statement 0.057
Ki-67 below mean (<40%) 10 (43) 2 (8)
Ki-67 over mean (≥ 40%) 5 (22) 6 (27)Page 3 of 8
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colon cancer tissue sections with known increased CAR
positivity were used [23]. The tumor proliferative capacity
was assessed immunohistochemically, using a mouse
anti-human Ki-67 antigen; IgG1k antibody (clone MIB-1,
Dakopatts) as previously described [24].
Evaluation of immunohistochemistry
The percentages of positively stained cells were obtained
by counting at least 1000 tumor cells in each case by two
independent observers (SET and IKS) blinded to the clin-
ical data with complete observer agreement. Specimens
were considered "positive" for CAR and Ki-67 when more
than 5% of the tumor cells were stained, while they were
characterized to present "high" CAR and Ki-67 expression
when the percentage of positively stained cells exceeded
the mean percentage value. The intensity of CAR immu-
nostaining was also estimated and graded on a three step
scale as: mild (+), moderate (++) and intense (+++). The
cellular pattern of distribution of CAR immunostaining
was characterized as membraneous and cytoplasmic. All
endometrial adenocarcinoma cases were Ki-67 positive,
presenting nuclear pattern of staining.
Statistical analysis
Chi-square tests were used to assess the association of CAR
positivity, overexpression and staining intensity with clin-
icopathological variables and tumor proliferative capac-
ity. Survival curves were constructed using the Kaplan-
Meier method and compared using the log-rank test. Cox
proportional hazard regression analysis was used to eval-
uate the effect of CAR positivity, level of expression (low
vs high level of CAR expression) and staining intensity as
prognostic factors on patient survival. A 2-tailed P < 0.05
was considered (statistically) significant. Statistical analy-
ses were performed using the software package SPSS for
Windows (version 11.0; SPSS Inc., Chicago, IL, USA).
Results
CAR positivity was noted in 23 out of 41 (56%) of the
examined endometrial adenocarcinoma cases (Table 1).
Representative CAR immunostaining is presented in Fig-
ure 1. The pattern of CAR distribution was both cytoplas-
mic and membraneous in all positive cases examined.
High CAR expression was noted in 8 out of 23 (35%) of
the positive cases (Table 2). The intensity of CAR immu-
nostaining was classified as mild in 11 (48%), moderate
in 10 (43%) and intense in 2 (9%) out of 23 positive cases
(Table 3).
CAR positivity was significantly associated with tumor
histological grade, as well differentiated tumors most fre-
quently presenting no CAR expression compared to mod-
erately and poorly differentiated ones. (P = 0.036, Table
1). High CAR expression showed a trend to be correlated
with increased proliferative capacity (P = 0.057, Table 2).
CAR staining intensity was significantly associated with
tumor histological type, as cases possessing squamous ele-
ments presented more frequently intense CAR immunos-
taining (P = 0.016, Table 3). CAR positivity, level of
Table 3: Associations between CAR staining intensity and clinicopathological characteristics of the 23 CAR positive endometrial 
adenocarcinoma cases
Clinicopathological characteristics CAR intensity
Mild (%) Moderate (%) Intense (%) P-value
Patients 11 (48) 10 (43) 2 (9)
Age (mean ± SD), years 63.2 ± 11.5 63.6 ± 11.2 52.5 ± 0.7 0.359
< 63 6 (26) 5 (22) 2 (9)
≥63 5 (22) 5 (22) 0 (0)
pStage (FIGO) 0.395
I 7 (30) 9 (39) 2 (9)
II 3 (14) 0 (0) 0 (0)
III 0 (0) 1 (4) 0 (0)
IV 1 (4) 0 (0) 0 (0)
Histological type 0.016
Positive for squamous elements 1 (4) 2 (9) 2 (9)
Negative for squamous elements 10 (44) 8 (34) 0 (0)
Histological grade 0.881
Well differentiated 1 (4) 1 (4) 1 (4)
Moderately differentiated 9 (40) 7 (30) 1 (5)
Poorly differentiated 1 (4) 2 (9) 0 (0)
Ki-67 protein statement 0.555
Ki-67 below mean (< 40%) 7 (31) 4 (17) 1 (4)
Ki-67 over mean (≥ 40%) 4 (17) 6 (26) 1 (5)Page 4 of 8
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associated with the other clinicopathological parameters
examined (Tables 1, 2 and 3).
The Kaplan-Meier product-limit method for overall anal-
ysis survival according to CAR positivity (positive vs nega-
tive CAR staining), level of expression (high vs low level of
CAR expression) and staining intensity (mild vs moderate
and intense CAR staining intensity) in patients with
endometrial adenocarcinoma did not reveal statistically
significant correlations (log-rank test, P = 0.799, P = 0.816
and P = 0.127, respectively) (data not shown). The sur-
vival of patients with tumors presenting moderate or
intense CAR staining intensity (mean survival rate 72.3 ±
11.0 months) was longer than those presenting mild
intensity (mean survival rate 55.6 ± 19.5 months); how-
ever the difference did not reach statistical significance in
univariate analysis (P = 0.127, data not shown).
Discussion
The expression of CAR in human tumors and tumor cell
lines has been subject of several studies [5,6,25-28] which
have detected this transmembrane protein in variable and
often low levels. The present study focused on the immu-
nohistochemical examination of CAR expression in
endometrial adenocarcinoma samples and revealed the
clinical significance of CAR in certain aspects of endome-
trial neoplasia, such as tumor differentiation, histological
type and proliferation. More to the point, CAR positivity
was noted in 56% of the examined cases. This incidence
of endometrial adenocarcinoma CAR positivity cannot be
considered among the highest ever found on tumor
malignancies, since Gu et al. have observed a 75% CAR
positivity on osteosarcoma samples; however, it is cer-
tainly higher than that of lung adenocarcinoma [29,30].
To this point, it should be noted the effectiveness of ade-
noviral gene therapy depends on the amount of CAR
expression on target cells. Thus, the current study rein-
forced the suitability for adenoviral gene therapy in the
case of endometrial adenocarcinoma.
Our study is the first report examining the clinical signifi-
cance of CAR expression in patients with endometrial ade-
nocarcinoma. We found that well differentiated tumors
more frequently presenting no CAR expression compared
to moderately and poorly differentiated ones. In this
aspect, Korn et al. also revealed a significant association
between CAR expression and tumor histological grade in
patients with gastrointestinal malignancies; however,
moderately to poorly differentiated tumors more fre-
quently demonstrating low or no CAR expression [31].
CAR expression was also reported to be increased with
increasing grade of tumor in breast cancer patients; how-
ever, this difference was not statistically significant [32].
Moreover, in the current study, high CAR expression
showed a trend to be correlated with increased prolifera-
tive capacity. In this context, CAR expression was reported
to modulate the proliferative capacity of cancer cells, in
vitro [13,16,18,33]. In fact, the presence of CAR was found
not only to facilitate viral uptake of adenovirus, but also
to inhibit cell growth in bladder cancer and malignant gli-
oma cells [13,16,18,33]. The latter is not in line with the
current findings and could be ascribed to the individual
characteristics among the different types of cancer. More-
over, our results were based on the in situ detection of CAR
protein by immunohistochemistry, while the potential
Intense immunostaining for CAR in tumor cells in representative endometrial adenocarcinoma cases (original magnification ×200)Figur 1
Intense immunostaining for CAR in tumor cells in representative endometrial adenocarcinoma cases (original magnification 
×200). A. Negative for squamous elements. B. Positive for squamous elements.Page 5 of 8
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cell lines or tumor cells injected into nude mice
[13,16,18,33]. We also found that CAR staining intensity
was significantly associated with the tumor histological
type. This result is in line with previous evidence where
higher rates of CAR expression were detected in lung squa-
mous cell carcinoma than in adenocarcinoma [30].
To our knowledge, there is limited data so far highlighting
to the prognostic value of CAR expression in cancer. In
this respect, our study is the first report examining the
clinical significance of CAR expression in the prognosis of
patients with endometrial adenocarcinoma. We did not
found any significant association of CAR positivity, level
of expression and staining intensity with patient survival.
It should be noted that the survival of patients with
tumors presenting moderate or intense CAR staining
(mean survival rate 72.3 ± 11.0 months) was longer than
those with mild (mean survival rate 55.6 ± 19.5 months);
however, this difference did not reach statistically signifi-
cance in univariate analysis (P = 0.127). In this context,
Martin et al. showed that elevated levels of CAR expres-
sion were significantly associated with poor overall sur-
vival in patients with breast cancer [32]. It has also been
shown that the soluble splice variants CAR 3/7 and CAR
4/7, but no the full-length hCAR were of independent
prognostic relevance for progression-free or overall sur-
vival of ovarian cancer patients [34].
In the last few years, the use of adenovirus vectors is gain-
ing increasingly interesting in order to advance new ther-
apeutic approaches against cancer. Thus, many tumor
samples have been examined for CAR expression, which
has generally been found to correlate with susceptibility
to transduction [5,18,28,35]. In several human malignan-
cies, including bladder and prostate carcinoma and gliob-
lastoma, CAR expression was downregulated during the
progression to malignancy [16,36,37]. In CAR-deficient
prostate and glioma tumor cell lines, expression of CAR
by transfection resulted in suppression of cell prolifera-
tion and decreased tumorogenicity [18,33]. CAR expres-
sion also inhibited cell proliferation and was associated
with modulations in the activity of the cell cycle regulators
p21-PIC and Rb in bladder cancer cells [16]. Importantly,
CAR dependent growth inhibition required the presence
of CAR-specific antibody which blocked homotypic adhe-
sion [16].
A strong correlation of CAR levels with the viral sensitivity
of any given cell has been reported [4-6]. Although the
normal cellular function of CAR is not known, some
researchers have suggested that CAR may serve as a cell-
cell adhesion molecule [38], while others have shown an
in vitro and in vivo tumor-suppressive role for CAR [33]. It
is thought that CAR can inhibit cancer growth by behav-
ing as a membrane receptor, which conveys its signal into
the nucleus, thus resulting in suppression of the prolifera-
tive mechanisms [13]. Moreover, reduced CAR expression
was shown to induce lung metastasis [39]. Overall, corre-
lating the CAR expression in all known tumor malignan-
cies with clinicopathological parameters cannot only
provide crucial information about its role in malignant
transformation, but it can also establish a better view for
future gene therapy approaches. Currently, Othman et al.
reported that endometriosis cells expressed higher levels
of CAR mRNA as compared with normal endometrial
cells [40]. In addition, it was shown that adenoviruses can
effectively transfect endometriosis cells in vitro. The dom-
inant negative mutants of Estrogen receptors (DN-ER)
delivered to endometriosis cells via an adenovirus
decreased cell proliferation, induced apoptosis and sup-
pressed cytokine production by these cells [40]. Such data
supported substantial evidence that adenovirus-mediated
delivery of DN-ER to endometriosis cells can be a poten-
tial therapeutic approach for endometriosis [40].
Conclusion
The data presented in this study revealed enhanced CAR
expression in endometrial adenocarcinoma specimens.
CAR protein expression was associated with important
clinicopathological parameters with respect to the diagno-
sis of patients with endometrial cancer. Although CAR
protein failed to predict patient survival, the current study
supports evidence for potential implication of CAR pro-
tein in endometrial carcinogenesis. The use of Ad vectors
in gene therapy needs an efficient and accurate system for
delivering the therapeutic gene into target cells [12]. In
this regard, CAR expression could be a surrogate marker
for monitoring and/or predicting the outcome of gene
therapy, while its increase might contribute to the upreg-
ulation of cellular sensitivity towards Ad infection [13]. It
is, however, without doubt that in order to understand the
physiological role of CAR in cellular function and prolif-
eration, a systematic approach towards the identification
of its natural ligand(s) should also be attempted.
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